Thomas G. Gross MD, PhD


​ 

Thomas G. Gross MD, PhD
Assoc ProfessorCollege of MedicineThomas.Gross@nationwidechildrens.org
Nationwide Children's Hospital 700 Children's Drive Columbus OH 43210
Phone:614-722-3552Fax: 614-722-3699
  • Non-Member

General Research Interest

pediatric lymphoma

Research Description

My research focus is in pediatric non-Hodgkin lymphoma (NHL).  As Chair of the Children’s Oncology Group (COG) NHL Committee, I supervise and facilitate clinical trials and correlative biology studies for North America and now working with European pediatric cooperative groups.  My particular interest is EBV associated post-transplant lymphoma and am PI for a NCI-funded clinical trial.

Transinstitutional Work

Send follow up email to Gross explaining what trans-institutional means, and he will send blurb

Current Publications

  • Lowe EJ, Gross TGAnaplastic large cell lymphoma in children and adolescents.Pediatr Hematol Oncol 30(6) 509-19 9/1/2013
  • Wistinghausen B, Gross TG, Bollard CPost-transplant lymphoproliferative disease in pediatric solid organ transplant recipients.Pediatr Hematol Oncol 30(6) 520-31 9/1/2013
  • Barth MJ, Goldman S, Smith L, Perkins S, Shiramizu B, Gross TG, Harrison L, Sanger W, Geyer MB, Giulino-Roth L, Cairo MSRituximab pharmacokinetics in children and adolescents with de novo intermediate and advanced mature B-cell lymphoma/leukaemia: a Children's Oncology Group report.Br J Haematol 162(5) 678-83 9/1/2013
  • Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch MDisseminated lymphoblastic lymphoma in children and adolescents: results of the COG A5971 trial: a report from the Children's Oncology Group.Br J Haematol 162(6) 792-801 9/1/2013
  • Smith SM, Burns LJ, van Besien K, Lerademacher J, He W, Fenske TS, Suzuki R, Hsu JW, Schouten HC, Hale GA, Holmberg LA, Sureda A, Freytes CO, Maziarz RT, Inwards DJ, Gale RP, Gross TG, Cairo MS, Costa LJ, Lazarus HM, Wiernik PH, Maharaj D, Laport GG, Montoto S, Hari PNHematopoietic cell transplantation for systemic mature T-cell non-hodgkin lymphoma.J Clin Oncol 31(25) 3100-9 9/1/2013
  • Bollard CM, Lim MS, Gross TGChildren's Oncology Group's 2013 blueprint for research: non-Hodgkin lymphoma.Pediatr Blood Cancer 60(6) 979-84 6/1/2013
  • Hitzler JK, He W, Doyle J, Cairo M, Camitta BM, Chan KW, Diaz Perez MA, Fraser C, Gross TG, Horan JT, Kennedy-Nasser AA, Kitko C, Kurtzberg J, Lehmann L, O'Brien T, Pulsipher MA, Smith FO, Zhang MJ, Eapen M, Carpenter PAOutcome of transplantation for acute myelogenous leukemia in children with Down syndrome.Biol Blood Marrow Transplant 19(6) 893-7 6/1/2013
  • Goldman S, Smith L, Anderson JR, Perkins S, Harrison L, Geyer MB, Gross TG, Weinstein H, Bergeron S, Shiramizu B, Sanger W, Barth M, Zhi J, Cairo MSRituximab and FAB/LMB 96 chemotherapy in children with Stage III/IV B-cell non-Hodgkin lymphoma: a Children's Oncology Group report.Leukemia 27(5) 1174-7 4/1/2013
  • Danner-Koptik KE, Majhail NS, Brazauskas R, Wang Z, Buchbinder D, Cahn JY, Dilley KJ, Frangoul HA, Gross TG, Hale GA, Hayashi RJ, Hijiya N, Kamble RT, Lazarus HM, Marks DI, Reddy V, Savani BN, Warwick AB, Wingard JR, Wood WA, Sorror ML, Jacobsohn DASecond malignancies after autologous hematopoietic cell transplantation in children.Bone Marrow Transplant 48(3) 363-8 3/1/2013
  • Maramattom LV, Hari PN, Burns LJ, Carreras J, Arcese W, Cairo MS, Costa LJ, Fenske TS, Lill M, Freytes CO, Gale RP, Gross TG, Hale GA, Hamadani M, Holmberg LA, Hsu JW, Inwards DJ, Lazarus HM, Marks DI, Maloney DG, Maziarz RT, Montoto S, Rizzieri DA, Wirk B, Gajewski JLAutologous and allogeneic transplantation for burkitt lymphoma outcomes and changes in utilization: a report from the center for international blood and marrow transplant research.Biol Blood Marrow Transplant 19(2) 173-9 2/1/2013
  • Termuhlen AM, Smith LM, Perkins SL, Lones M, Finlay JL, Weinstein H, Gross TG, Abromowitch MOutcome of newly diagnosed children and adolescents with localized lymphoblastic lymphoma treated on Children's Oncology Group trial A5971: a report from the Children's Oncology Group.Pediatr Blood Cancer 59(7) 1229-33 12/15/2012
  • Gross TG, Orjuela MA, Perkins SL, Park JR, Lynch JC, Cairo MS, Smith LM, Hayashi RJLow-dose chemotherapy and rituximab for posttransplant lymphoproliferative disease (PTLD): a Children's Oncology Group Report.Am J Transplant 12(11) 3069-75 11/1/2012
  • Skeens M, Pai V, Garee A, Termuhlen AM, Bajwa RP, Gross TG, Soni STwice daily i.v. bolus tacrolimus infusion for GVHD prophylaxis in children undergoing stem cell transplantation.Bone Marrow Transplant 47(11) 1415-8 11/1/2012
  • Patel JL, Smith LM, Anderson J, Abromowitch M, Campana D, Jacobsen J, Lones MA, Gross TG, Cairo MS, Perkins SLThe immunophenotype of T-lymphoblastic lymphoma in children and adolescents: a Children's Oncology Group report.Br J Haematol 159(4) 454-61 11/1/2012
  • Glotz D, Chapman JR, Dharnidharka VR, Hanto DW, Castro MC, Hirsch HH, Leblond V, Mehta AK, Moulin B, Pagliuca A, Pascual J, Rickinson AB, Russo FP, Trappe RU, Webster AC, Zuckermann AO, Gross TGThe Seville expert workshop for progress in posttransplant lymphoproliferative disorders.Transplantation 94(8) 784-93 10/27/2012
  • Soni S, Skeens M, Termuhlen AM, Bajwa RP, Gross TG, Pai VLevetiracetam for busulfan-induced seizure prophylaxis in children undergoing hematopoietic stem cell transplantation.Pediatr Blood Cancer 59(4) 762-4 10/1/2012
  • Freytes CO, Zhang MJ, Carreras J, Burns LJ, Gale RP, Isola L, Perales MA, Seftel M, Vose JM, Miller AM, Gibson J, Gross TG, Rowlings PA, Inwards DJ, Pavlovsky S, Martino R, Marks DI, Hale GA, Smith SM, Schouten HC, Slavin S, Klumpp TR, Lazarus HM, van Besien K, Hari PNOutcome of lower-intensity allogeneic transplantation in non-Hodgkin lymphoma after autologous transplantation failure.Biol Blood Marrow Transplant 18(8) 1255-64 8/1/2012
  • Veys P, Wynn RF, Ahn KW, Samarasinghe S, He W, Bonney D, Craddock J, Cornish J, Davies SM, Dvorak CC, Duerst RE, Gross TG, Kapoor N, Kitko C, Krance RA, Leung W, Lewis VA, Steward C, Wagner JE, Carpenter PA, Eapen MImpact of immune modulation with in vivo T-cell depletion and myleoablative total body irradiation conditioning on outcomes after unrelated donor transplantation for childhood acute lymphoblastic leukemia.Blood 119(25) 6155-61 6/21/2012
  • Okano M, Gross TGAcute or chronic life-threatening diseases associated with Epstein-Barr virus infection.Am J Med Sci 343(6) 483-9 6/1/2012

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James) 300 W. 10th Ave. Columbus, OH 43210 Phone: 1-800-293-5066 | Email: jamesline@osumc.edu